皮下植入式心律转复除颤器长期结局:法国全国HONEST研究
HONEST研究为法国全国性学术观察研究,纳入2012-2019年98.2%的S-ICD植入患者,共4924例,中位随访5年。5年不恰当电击累积发生率13.8%,早期电池耗竭10.8%,感染2.4%,导线功能障碍1.5%,再手术16.9%。SMART Pass滤波显著减少不恰当电击(HR 0.67)。
要点
- 5年不恰当电击累积发生率13.8%,男性、肥胖、ARVC及合并起搏器为独立危险因素。
- 5年再手术率16.9%,明确S-ICD拔除率8.4%,需心脏起搏3.1%。
核心结论
- S-ICD治疗5年不恰当电击累积发生率13.8%,SMART Pass滤波可显著降低该风险。
- 无效电击或未识别心律失常发生率仅0.2%,S-ICD相关死亡罕见。
研究设计与样本
- HONEST为法国全国性学术观察研究,纳入2012-2019年98.2%的S-ICD植入患者。
- 共4924例患者,平均年龄49.9±15岁,76.7%男性,63.0%为一级预防。
- 5年临床终点由中心化裁定。
主要发现
- 5年不恰当电击累积发生率13.8%,早期电池耗竭10.8%,感染2.4%,导线功能障碍1.5%,慢性不适1.4%。
- 5年再手术率16.9%,需心脏起搏3.1%,明确S-ICD拔除8.4%。
- 547例死亡(11.1%),其中心血管死亡53.9%,包括26例猝死,8例为S-ICD/操作相关,无拔除相关死亡。
关键数值与推荐
- 5年不恰当电击累积发生率13.8%,早期电池耗竭10.8%,感染2.4%,导线功能障碍1.5%,慢性不适1.4%。
- 5年再手术率16.9%,需心脏起搏3.1%,明确S-ICD拔除8.4%。
- 不恰当电击患者中约1%发生诱发性室颤(1例死亡),10%接受装置拔除。
- 无效电击或未识别心律失常发生率0.2%。
临床怎么用
- S-ICD长期随访需关注不恰当电击、电池耗竭及再手术风险。
- 对男性、肥胖、ARVC或合并起搏器患者,应加强不恰当电击预防。
- SMART Pass滤波可作为减少不恰当电击的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Although use of the subcutaneous implantable cardioverter defibrillator (S-ICD) is increasing, evidence from industry-independent and unselected populations remains limited. METHODS: HONEST is a ongoing nationwide academic observational study enrolling 98.2% of patients implanted with an S-ICD across France (2012-2019). Five-year clinical endpoints were centrally adjudicated. RESULTS: Overall, 4924 patients were enrolled (mean age 49.9 ± 15 years, 76.7% male, 63.0% for primary prevention). Implants used general anaesthesia (78.9%), and defibrillation testing (82.6%). Perioperative complications (within 30 days) occurred in 4.4%. At 5 years, cumulative incidence rates were 13.8% for inappropriate shocks, 10.8% for early battery depletion, 2.4% for infections, 1.5% for lead dysfunction, and 1.4% for chronic discomfort. Reoperation was required in 16.9%, need for cardiac pacing in 3.1%, and definite S-ICD extraction in 8.4%. Inappropriate shocks were independently associated with male sex (hazard ratio [HR] 1.29, 95% confidence interval [CI] 1.14-1.46, P < .001), obesity (HR 1.35, 95% CI 1.02-1.79, P = .032), arrhythmogenic right ventricular cardiomyopathy (HR 1.70, 95% CI 1.03-2.81, P = .036), and the presence of a pacemaker (HR 2.20, 95% CI 1.16-4.17, P = .016). SMART Pass filtering significantly reduced inappropriate shocks (HR 0.67, 95% CI 0.50-0.89, P = .007). Among patients with inappropriate shocks, ∼1% developed induced ventricular fibrillation (one fatality), and 10% underwent device extraction. Ineffective shocks or undetected arrhythmias occurred in only 0.2%. Among 547 deaths (11.1%), 53.9% were cardiovascular, including 26 sudden deaths, and 8 were S-ICD/procedure-related, with none related to S-ICD extraction. CONCLUSIONS: This nationwide study refines the long-term event profile of S-ICD therapy and may inform clinical practice and device selection.
引用
- Kerkouri F, Marquié C, Boveda S, et al. Long-term outcomes of subcutaneous implantable cardioverter defibrillators: the French nationwide HONEST study. Eur Heart J. 2026. PMID: 41416696. doi:10.1093/eurheartj/ehaf918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。